These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19954102)

  • 21. Recombinant human erythropoietin in cancer-related anemia: an evidence-based review.
    Desai J; Demetri GD
    Best Pract Res Clin Haematol; 2005; 18(3):389-406. PubMed ID: 15792913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Standards, Options, and Recommendations for using erythropoietin in cancerology].
    Spaëth D; Marchal C; Blanc-Vincent MP
    Bull Cancer; 1998 Apr; 85(4):337-46. PubMed ID: 9752298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer.
    Beguin Y
    Med Oncol; 1998 Aug; 15 Suppl 1():S38-46. PubMed ID: 9785336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Anemia in lung cancer patients].
    Méric JB; Morère JF;
    Bull Cancer; 2005 May; 92(5):439-44. PubMed ID: 15932807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma.
    Ludwig H; Pecherstorfer M; Leitgeb C; Fritz E
    Stem Cells; 1993 Sep; 11(5):348-55. PubMed ID: 8241947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risks and benefits of erythropoiesis-stimulating agents in cancer management.
    Beutel G; Ganser A
    Semin Hematol; 2007 Jul; 44(3):157-65. PubMed ID: 17631180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EPO in cancer anemia: benefits and potential risks.
    Milano M; Schneider M
    Crit Rev Oncol Hematol; 2007 May; 62(2):119-25. PubMed ID: 17197190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Updating 1999 of Standards, Options and Recommendations (SOR) for the clinical use of erythropoietin in oncology. FEDERATION OF THE FRENCH CANCER CENTRES (FNCLCC)].
    Spaëth D; Marchal C; Bataillard A; Blanc-Vincent MP
    Bull Cancer; 1999; 86(7-8):631-9. PubMed ID: 10477381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anemia in the critically ill.
    Shander A
    Crit Care Clin; 2004 Apr; 20(2):159-78. PubMed ID: 15135458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The blue cross blue shield assessment technology review: summary of findings.
    Bennett CL
    Best Pract Res Clin Haematol; 2005; 18(3):423-31. PubMed ID: 15792916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of cancer-related anemia.
    Badzek S; Curić Z; Krajina Z; Plestina S; Golubić-Cepulić B; Radman I
    Coll Antropol; 2008 Jun; 32(2):615-22. PubMed ID: 18756919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Phase II clinical study of recombinant human erythropoietin on the anemia associated with multiple myeloma].
    Urabe A; Mizoguchi H; Takaku F; Miyazaki T; Yachi A; Niitsu Y; Miura Y; Mutoh Y; Fujioka S; Nomura T
    Rinsho Ketsueki; 1993 Aug; 34(8):919-27. PubMed ID: 8411646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. rHuEPO and treatment outcomes: the preclinical experience.
    Ludwig H
    Oncologist; 2004; 9 Suppl 5():48-54. PubMed ID: 15591422
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Erythropoietin treatment of anemia associated with multiple myeloma (MM) and myelodysplastic syndrome (MDS)].
    Qiao ZH
    Zhonghua Zhong Liu Za Zhi; 1993 Mar; 15(2):122-4. PubMed ID: 8223121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is erythropoietin treatment safe and effective in myeloma patients receiving hemodialysis?
    Caillette A; Barreto S; Gimenez E; Labeeuw M; Zech P
    Clin Nephrol; 1993 Sep; 40(3):176-8. PubMed ID: 8403574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma.
    Katodritou E; Dimopoulos MA; Zervas K; Terpos E
    Cancer Treat Rev; 2009 Dec; 35(8):738-43. PubMed ID: 19733008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Tumor anemia. Overview of the role of human recombinant erythropoietin (r-hu-EPO) in treatment of tumor anemia].
    Monnerat C; Leyvraz S
    Praxis (Bern 1994); 1999 Jan; 88(5):178-88. PubMed ID: 10067375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of anaemia in patients with malignancy: implications for the clinical use of recombinant human erythropoietin.
    Cazzola M
    Med Oncol; 2000 Nov; 17 Suppl 1():S11-6. PubMed ID: 11188780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. rHuEPO and improved treatment outcomes: potential modes of action.
    Blackwell K; Gascón P; Sigounas G; Jolliffe L
    Oncologist; 2004; 9 Suppl 5():41-7. PubMed ID: 15591421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.